Abstract: The invention relates to a method and system for the environmental remediation of materials that are contaminated with heavy minerals, such as heavy metals. The invention finds utility in removing heavy minerals from materials such as soils, sediments, mine tailings and ores. The invention provides a means for removing heavy minerals from contaminated materials without the use of water while reducing the generation of dust. Thus, the invention provides an environmentally friendly method for the remediation of sites that are contaminated with heavy minerals.

Abstract: The invention relates to a method and system for the environmental remediation of materials that are contaminated with heavy minerals, such as heavy metals. The invention finds utility in removing heavy minerals from materials such as soils, sediments, mine tailings and ores. The invention provides a means for removing heavy minerals from contaminated materials without the use of water while reducing the generation of dust. Thus, the invention provides an environmentally friendly method for the remediation of sites that are contaminated with heavy minerals.

Abstract: The invention relates to a method and system for the environmental remediation of materials that are contaminated with heavy minerals, such as heavy metals. The invention finds utility in removing heavy minerals from materials such as soils, sediments, mine tailings and ores. The invention provides a means for removing heavy minerals from contaminated materials without the use of water while reducing the generation of dust. Thus, the invention provides an environmentally friendly method for the remediation of sites that are contaminated with heavy minerals.

Abstract: The invention relates to a method and system for the environmental remediation of materials that are contaminated with heavy minerals, such as heavy metals. The invention finds utility in removing heavy minerals from materials such as soils, sediments, mine tailings and ores. The invention provides a means for removing heavy minerals from contaminated materials without the use of water while reducing the generation of dust. Thus, the invention provides an environmentally friendly method for the remediation of sites that are contaminated with heavy minerals.

Abstract: A medicament for treating cystitis and a method of treatment are provided. An agent to repair the damaged glycosaminoglycan (“GAG”) layers lining the urothelium, noted in cystitis, such as pentosan polysulfate, hyaluronic acid, chondroitin, etc., is provided in a liposomal carrier. Cystitis is treated by intravesically administering to a patient a therapeutically effective dose of the medicament.

Abstract: The invention relates to a method and system for the environmental remediation of materials that are contaminated with heavy minerals, such as heavy metals. The invention finds utility in removing heavy minerals from materials such as soils, sediments, mine tailings and ores. The invention provides a means for removing heavy minerals from contaminated materials without the use of water while reducing the generation of dust. Thus, the invention provides an environmentally friendly method for the remediation of sites that are contaminated with heavy minerals.

Abstract: A medicament for treating cystitis and a method of treatment are provided. An agent to repair the damaged glycosaminoglycan (“GAG”) layers lining the urothelium, noted in cystitis, such as pentosan polysulfate, hyaluronic acid, chondroitin, etc., is provided in a liposomal carrier. Cystitis is treated by intravesically administering to a patient a therapeutically effective dose of the medicament.

Abstract: A medicament for treating cystitis and a method of treatment are provided. An agent to repair the damaged glycosaminoglycan (“GAG”) layers lining the urothelium, noted in cystitis, such as pentosan polysulfate, hyaluronic acid, chondroitin, etc., is provided in a liposomal carrier. Cystitis is treated by intravesically administering to a patient a therapeutically effective dose of the medicament.

Abstract: The invention relates to a method and system for the environmental remediation of materials that are contaminated with heavy minerals, such as heavy metals. The invention finds utility in removing heavy minerals from materials such as soils, sediments, mine tailings and ores. The invention provides a means for removing heavy minerals from contaminated materials without the use of water while reducing the generation of dust. Thus, the invention provides an environmentally friendly method for the remediation of sites that are contaminated with heavy minerals.

Abstract: The invention relates to a method and system for the environmental remediation of materials that are contaminated with heavy minerals, such as heavy metals. The invention finds utility in removing heavy minerals from materials such as soils, sediments, mine tailings and ores. The invention provides a means for removing heavy minerals from contaminated materials without the use of water while reducing the generation of dust. Thus, the invention provides an environmentally friendly method for the remediation of sites that are contaminated with heavy minerals.

Abstract: The invention relates to a method and system for the environmental remediation of materials that are contaminated with heavy minerals, such as heavy metals. The invention finds utility in removing heavy minerals from materials such as soils, sediments, mine tailings and ores. The invention provides a means for removing heavy minerals from contaminated materials without the use of water while reducing the generation of dust. Thus, the invention provides an environmentally friendly method for the remediation of sites that are contaminated with heavy minerals.

Abstract: A medicament for treating cystitis and a method of treatment are provided. The medicament comprises a stromal vascular fraction provided in a liposomal carrier. Optionally, the medicament also controls one or more additional agents, such as a growth factor, glycosaminoglycan, DMSO, and/or another small molecule used to treat cystitis or having an effect on human stem cells. Cystitis is treated by intravesically administering to a patient a therapeutically effective dose of the medicament. The SVF can be derived from a patient's own adipose cells via liposuction.

Abstract: A medicament for treating cystitis and a method of treatment are provided. An agent to repair the damaged glycosaminoglycan (“GAG”) layers lining the urothelium, noted in cystitis, such as pentosan polysulfate, hyaluronic acid, chondroitin, etc., is provided in a liposomal carrier. Cystitis is treated by intravesically administering to a patient a therapeutically effective dose of the medicament.

Abstract: A device and methods for the real-time monitoring of stem cells in a stem cell transplant. The device comprises a linear member and particle detection device configured to occupy the lumen of a catheter while the catheter is in place to administer a stem cell transplant to a delivery site in the body of a patient. Monitoring of the stem cells permits the device to provide signals to a computer processor for the determination of one or more characteristics of stem cells in the stem cell transplant.

Abstract: A device and methods for the real-time monitoring of stem cells in a stem cell transplant. The device comprises a linear member and particle detection device configured to occupy the lumen of a catheter while the catheter is in place to administer a stem cell transplant to a delivery site in the body of a patient. Monitoring of the stein cells permits the device to provide signals to a computer processor for the determination of one or more characteristics of stein cells in the stein cell transplant.

Abstract: A method for introducing a drug, imaging agent and/or other chemical agent into the systemic circulation comprises providing a the drug, imaging agent and/or other chemical agent in liposomes having a mean diameter of less than about 200 nm, preferably less than about 80 nm, as determined by negative-staining transmission electron microscopy. The liposomes are orally administered. It has been found that liposomes of such small sizes are not absorbed by the macrophages in the Peyer's patches of the gut, but instead are introduced into the venous circulation from the Peyer's patches, and then through the portal vein or inferior vena cava system, through the heart, and into the systemic circulation.

Abstract: A method is provided for inducing a systemic immune response to an antigen. The method comprises providing a liposomal preparation comprising lyophilized liposomes containing at least one antigen. The liposomes have at least two sizes, before lyophilization, selected from small liposomes having a size, before lyophilization, of from about 20 nm to about 1 micron, medium liposomes having a size, before lyophilization, of from about 1 micron to about 3 microns, and large liposomes having a size, before lyophilization, of from about 3 microns to about 20 microns. An effective amount of the liposomal preparation is administered to a mammal, whereby sufficient antigen containing liposomes are absorbed in the Peyer's patches of the gut of the mammal and are taken up by macrophages in the Peyer's patches to stimulate a systemic immune response.

Abstract: A method for imaging diseased tissue is provided. The method provides delivering to the diseased tissue a liposomal imaging agent comprising liposomes containing an imaging agent. The liposomal imaging agent is bound to an antibody by an antigenic linker so that the antibody binds the liposomal imaging agent to the diseased tissue. The liposomes are broken to release the imaging agent using a catheter, and the imaging agent is viewed using an imaging technique. The tissue can also be treated by delivering a therapeutic agent to the tissue using the catheter, for example, within the liposomes of the liposomal imaging agent.

Abstract: A method is provided for inducing a systemic immune response to an antigen selected from inactivated HIV I and HIV II antigens in a mammal. The method comprises orally administering lyophilized multilaminar liposomes containing the antigen. The liposomes have a size of from 20 nm to 20 microns. The antigen-containing liposomes are absorbed in the Peyer's patches of the gut. Sufficient antigen-containing liposomes are taken up by macrophages in the Peyer's patches to induce a systemic immune response to the antigen.

Abstract: A method is provided for inducing a systemic immune response to an antigen. The method comprises providing a liposomal preparation comprising lyophilized liposomes containing at least one antigen. The liposomes have at least two sizes, before lyophilization, selected from small liposomes having a size, before lyophilization, of from about 20 nm to about 1 micron, medium liposomes having a size, before lyophilization, of from about 1 micron to about 3 microns, and large liposomes having a size, before lyophilization, of from about 3 microns to about 20 microns. An effective amount of the liposomal preparation is administered to a mammal, whereby sufficient antigen containing liposomes are absorbed in the Peyer's patches of the gut of the mammal and are taken up by macrophages in the Peyer's patches to stimulate a systemic immune response.